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APC-INDEPENDENT EXPANSION OF IMMUNOREGULATORY TR1 CELLS
FROM STEM CELL SOURCES FOR ADOPTIVE IMMUNOTHERAPY
Morales-Tirado, V., Van Der Merwe, M., Luszczek, W., Pillai, A. St.
Jude Children’s Research Hospital, Memphis, TN
Immunotherapy with both adaptive and innate regulatory T cells
facilitates induction of transplant tolerance, including the preven-
tion and treatment of GVHD. Current strategies to expand regula-
tory Tr1 cells from CD31CD41CD25neg conventional T cells
include culture with IL-10 and APCs (Groux, et al., Nature,
1997; Gregori et al., Methods Mol. Biol., 2007) and a non-APC
dependent protocol utilizing anti-CD3 and IL-2 combined with
antibody cross-linking of the innate complement inhibitor I co-
factor protein (CD46) (Kemper et al., Nature, 2003). Optimizing
a robust APC-independent means of Tr1 cell generation is of par-
ticular utility to hematopoietic cell transplant (HCT) immunother-
apy, as it offers potential for large-scale Tr1 cell expansion from
autologous or allogeneic cell sources without need for re-separa-
tion of Tr1 cells from host or donor APCs prior to infusion. To
determine the optimal methods and cellular products for non-
APC-dependent expansion of Tr1 suppressors, we performed
anti-CD46-mediated expansion of Tr1 cells for 21-28 days from
various potential cellular therapy sources. CD31CD41CD25neg
cells were FACS-isolated at . 98% purity and underwent parallel
ex vivo expansions from adult peripheral blood apheresis units (PB-
Tr1), adult bone marrow (BM-Tr1) and cord blood (CB-Tr1) us-
ing low-dose IL-2, anti-CD3, and antibody-crosslinking of
CD46, without addition of IL-10 or APCs, to derive a uniform
population of CD31CD41CD25int/1Foxp3lo cells (. 95% conver-
sion of CD25negFoxp3lo to CD25int/1Foxp3lo cells, regardless of
cellular product type). Differential levels of expansion of Tr1 cells
occurred according to the source of cell product, with greatest fold-
expansion in PB-Tr1 [mean absolute numbers at day 21 fromy105
starting CD31CD41CD25neg cells: PB-Tr1 (n 5 3): 2.5 6 0.8 
107; BM-Tr1 (n 5 2): 7.2  105; CB-Tr1 (n 5 4): 5.6 6 0.3 
105]. By day 14-21 of expansion, PB-Tr1 cells secrete IL-10 and
IL-5, very low levels of IL-2 and IFN-g, and no IL-4 or IL-17
by anti-CD2/CD3/CD28 bead stimulation and Luminex super-
natant assay, and they demonstrate suppressor function against
sorted autologous CFSE-labeled CD31CD41CD25neg responders
in 72-hour MLR using irradiated allogeneic APC stimulators
(Table 1). We are currently optimizing similar protocols for expan-
sion of BM-Tr1 and CB-Tr1 to allow application in tolerance in-
duction and immunotherapy after HCT from each of these cellular
therapy sources.




Mean ± SD %
ProliferationP value vs
R only (t-test)P value vs 1:0
(+Stim) (t-test)R only 14.8 ± 3.1 — —
1:0 (+ Stim) 38.0 ± 8.8 0.002 —
1:1 (+ Stim) 21.3 ± 3.5 0.044 0.010
1:5 (+ Stim) 13.8 ± 2.8 0.674 0.003*Stim5 allogeneic 3300 cGy-irradiated APC stimulators170
MULTIVIRUS-SPECIFIC CTL FOR ADOPTIVE TRANSFER USING IN VITRO
PEPMIX STIMULATION
Gerdemann, U., Vera, J.F., Katari, U.L., Keirnan, J.M., Christin, A.S.,
Heslop, H.E., Rooney, C.M., Leen, A.M. Baylor College of Medicine,
Methodist Hospital, and Texas Children’s Hospital, Houston, TX
We and others have shown that viral infections in allo-HSCT
recipients can be prevented/treated by the adoptive transfer of vi-
rus-specific CTL. However, conventional CTL manufacture has
taken . 3 months. We recently developed a protocol to rapidlygenerate CTLs (rCTLs) using DCs nucleofected with viral anti-
gen-encoding DNA plasmids as APCs and expansion in a gas per-
meable bioreactor (G-Rex) in IL71IL4, which reduces
manufacturing time to 16 days. To further streamline production
without affecting potency, we are now assessing whether multivirus
CTL can be generated by directly stimulating donor PBMCs with
clinically applicable pepmixes (15mer peptide libraries) spanning
viral antigens.
We isolated PBMCs from 4 healthy donors and generated rCTL
using plasmid-nucleofected DCs or by directly stimulating bulk
PBMCs using pepmixes spanning the same antigens encoded by
the plasmids (EBV-EBNA1, LMP2, BZLF1; CMV-IE1, pp65
and Adv-Hexon, Penton) (pCTL). Subsequently the activated cells
were expanded as outlined above. We compared the phenotype,
proliferation, specificity and function of each cell population.
There was no significant difference in the rate of expansion
(rCTL vs pCTL, 8.6 vs 7.1 fold). Similarly, both were phenotypi-
cally indistinguishable, with a dominance of CD4 T cells (70.5 vs
74.2%) expressing CD62L (77 vs 61%). Both rCTL and pCTL
were specific for the stimulating antigens as measured by IFNg
ELIspot with a median of 100 vs 55 EBNA1, 45 vs 47 LMP2, 55
vs 32 BZLF1, 195 vs 232 IE1, 3927 vs 4472 pp65, 525 vs 535
Hexon, 372 vs 782 Penton SFC/1x106 CTL. rCTL and pCTL
lysed EBV (16 vs 19%), Adv (27 vs 34%) and CMV targets (42
vs 49% E:T 80:1). Finally, to evaluate whether stimulation using
15mer peptides, which contain all CD8 but possibly not all CD4
epitopes, results in loss of CD41 specificity we generated pCTL
using either 15-or 30mer peptides spanning a region of Hexon pre-
dominantly recognized by CD41 T cells. Phenotypically the CTL
were similar (CD41 56 vs 60%; CD81 21 vs 16%) and epitope
specificity, as evaluated by stimulation with peptide pools, demon-
strated slightly broader specificity using 15-over 30mer peptides
with a mean of 10 vs 7 pools recognized.
In summary, we can efficiently generate polyclonal multivirus
CTLs by directly stimulating PBMCs with pepmixes. This approach
is clinically applicable, requires a starting blood volume of only 15ml,
and reduces manufacturing time to\10 days, with a consequent re-
duction in cost and complexity.171
SENESCENCE OF CULTURED BONE MARROW STROMAL CELLS
Ren, J.1, Stroncek, D.1, Jin, P.1, Castiello, L.1, Tran, K.1,
Balakumaran, A.2, Robey, P.2, Sabatino, M.1 1National Institutes of
Health, Bethesda, MD; 2National Institutes of Health, Bethesda, MD
Bone marrow stromal cell (BMSC) therapy is effective for treat-
ing acute-Graft versus Host Disease. Clinical BMSCs are produced
by serial passage of adherent cells from marrow aspirates. Multiple
passages allow for the production of large quantities of human
BMSCs, but expansion is limited by cell senescence. We assessed
the nature of BMSC changes associated with multiple passages in
order to better understand the nature and impact of senescence
on human BMSCs and to identify potential senescence associated
biomarkers. BMSCs from marrow aspirates of 5 healthy subjects
were cultured in flasks and passed serially until cell growth stopped
between the 8th to 12th passages. Early (passage 1 and 2, n10) and
late passage cells (passages 5 through 11, n15) were selected based
on their replicative lifespan and compared. Senescence was associ-
ated with a change to a flattened morphology and increased senes-
cence associated beta-galactosidase (SA b-gal) staining. The
BMSCs were analyzed by global transcriptome analysis with an
oligonucleotide microarray with .44,000 probes. Unsupervised hi-
erarchical clustering analysis separated the 25 samples into two
clusters, one with all early and a second with all late passage
BMSCs and a total of 1,739 genes were differentially expressed.
Ingenuity pathway analysis revealed that genes highly expressed
in the early passage BMSCs belonged to several immune pathways:
cell-mediated immune response, humoral immune responses, hy-
persensitive responses, and lymphoid tissue structure and develop-
ment. Genes highly expressed in the late passage BMSCs belonged
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metabolism pathways. Hierarchical clustering analysis of 347 dif-
ferentially expressed cell cycle and apoptosis genes again separated
the early and late passage cells into two groups and a node of genes
up-regulated in late passages cells included two genes involved with
replication senescence, cyclin-dependent kinase inhibitor 1A (p21,
Cip1) (CDKN1A) and cyclin-dependent kinase inhibitor 2A (mel-
anoma, p16, inhibits CDK4) (CDKN2A) and one that inhibits
TRAIL mediated apoptosis, tumor necrosis factor receptor super-
family, member 10d (TNFRSF10D, DCR2, CD264). Flow cytom-
etry analysis confirmed greater expression of TNFRS10D on late
passage cells. BMSC senescence is associated with distinct molecu-
lar changes. Early passage BMSCs may have more immune modu-
latory properties.172
THERAPEUTIC POTENTIAL OF GAMMADELTA T-CELLS IN CONTROLLING
CMV AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
van Dorp, S.1, Kersting, S.2, Pietersma, F.L.1, Scheper, W.A.2, Hol, S.1,
Heijhuurs, S.2, Marcu-Malina, V.2, Plachter, B.3, van Baarle, D.1,
Kuball, J.H.E.1,2 1UMCU, Utrecht, Netherlands; 2UMCU, Utrecht,
Netherlands; 3 Johannes Gutenberg-Universit€at, Mainz, Germany
Introduction: Allogeneic stem cell transplantation (allo-SCT) is
hampered by GvHD, infections like CMV and relapse of disease.
Gammadelta T-cells (gdT-cells) seem to be important in virus con-
trol but also in malignancy control. CMV infections are associated
with an increased expansion of Vd11T cells. Therefore, we investi-
gated frequency and function of gdT-cells after allo-SCT in order to
assess their therapeutic potential.
Methods: PBMCs at time points within 3 months after allo-SCT
of 17 patients were sampled. CMV viral load was monitored by
PCR. Phenotype and frequency of gdT-cells and alpha beta T-cells
(abT-cells) were analyzed by flow cytometry. GdT-cells of 2 pa-
tients with CMV reactivation were isolated and expanded. Fre-
quency and clonality of Vd11, Vd21 and Vd31T cells were
measured with spectratyping. The reactivity against CMV infected
fibroblasts of Vd2- and Vd21T-cells was tested using an IFN-g
ELISPOT.
Results:We observed an increased expansion of Vd11T-cells after
allo-SCT in patients during CMV reactivation as assessed by flow
cytometry and spectratyping. Furthermore Vd11 but not Vd21T-
cells from these patients reacted against CMV infected fibroblasts.
Moreover, following pp65-reactive abT-cells in HLA-A21 patients
indicated that Vd11T cells precede an abT-cell response. Finally
Vd11T cells were able to induce antigen independent maturation
of dendritic cells (DC) via CD1c.
Conclusion: GdT-cells are present in patients after allo-SCT, have
the potential to eradicate CMV infected fibroblasts and possibly the
potential to spread an immune response to abT-cells via DC matu-
ration. This strongly supports the idea to explore gdT-cells as cell
population for immune interventions after allo-SCT.173
DEVELOPMENT OF CD19-SPECIFIC CENTRAL MEMORY DERIVED T CELL
PRODUCTS FOR THE TREATMENT OF CD191 HEMATOLOGIC MALIGNAN-
CIES
Wang, X.1, Hamlett, A.1, Bautista, C.1,Wong, C.L.W.1, Chang,W.-C.1,
Ostberg, J.R.1, Forman, S.J.1, Jensen, M.C.2 1City of Hope National
Medical Center, Duarte, CA; 2Seattle Children’s Research Institute,
Seattle, WA
A key parameter affecting the therapeutic potency of adoptive T
cell transfer is the extent to which infused cells persist and expand
in vivo. Ex vivo expanded CD81 effector T cells derived from
CD45RO1CD62L1 central memory (TCM) precursors are epige-
netically programmed to persist and revert to memory T cells fol-lowing adoptive transfer. TCM are a rare subpopulation of
lymphocytes in peripheral blood, therefore we sought to develop
a clinical-scale immunomagnetic purification method to isolate
CD81 TCM for subsequent genetic modification to express CD19-
specific chimeric antigen receptors (CAR). Using a two step process
by which monocytes, na€ıve and CD41T cells are first depleted from
PBMC, followed by positive selection of CD62L1 TCM, we have
found that CD81TCM can be enriched from 2-8% to. 80% purity.
Following isolation, CD81 TCM can be activated with CD3/CD28
Dynal beads, transduced two days later with cGMP grade self-inac-
tivating lentivirus (MOI 1.5), then expanded with 50U/ml IL-2 and
0.5ng/ml IL-15. This process results in the procurement of cell num-
bers for clinical use within 3-6 weeks without further ex vivo stimu-
lation (i.e., 1-3x109 final product from 7-15x106 CD81TCM). These
TCM -derived effector cell products (TE(CM)) are 80-90%CAR
1 and
exhibit CD19-specific cytolytic function and IFN-g production. Ad-
ditionally, these products consist of a broad repertoire of TE(CM)
based on TCR Vb usage, retain expression of central memory
markers such as CD62L/CD28, and, upon adoptive transfer into im-
munodeficient NOG mice, exhibit in vivo engraftment fitness in
a huIL-15 dependent manner. This process has undergone a series
of full scale qualification runs under cGMP and our group will be ap-
plying CD19-specific CD81 TE(CM) for post autologous HSCT
adoptive therapy of high risk lymphoma as an innovative strategy
to deliver engineered GVL effectors for eradication of minimal re-
sidual disease.174
BIOTHERAPY ORDER ENTRY (BOE) – ELECTRONIC PHYSICIAN ORDERS
FOR CELLULAR THERAPY PRODUCTS
Sturtevant, O.J.1, Schott, D.M.1, Brzezinski, P.1, Marston, E.2,
Gatzos, L.2, Barbetti, S.2, Canning, C.1, Kao, G.1, Antin, J.1,
Soiffer, R.1, Ritz, J.1 1Dana Farber Cancer Institute, Boston, MA;
2Partners Healthcare Inc, Boston, MA
Electronic systems for physician orders have largely focused
on medications but orders for cellular products are also a poten-
tial source of communication errors that may affect patient
safety. As part of a quality improvement effort, we developed
and implemented an electronic order entry system for therapeu-
tic cellular products of various types. Biotherapy Order Entry
(BOE) was built to include three types of physician orders: 1)
cell collection, 2) cell processing and 3) product release for ad-
ministration. For each order type, electronic templates are
created based on requirements of specific treatment plans or
IRB-approved clinical research protocols. Each order set imports
patient demographics from the hospital registration system and
patient registration information from the Quality Assurance for
Clinical Trials (QACT) information system. Individual templates
for each treatment plan or research protocol are reviewed and
approved before activation and orders can only be placed after
consent to a treatment plan or protocol has been confirmed.
For example, template orders for collection of hematopoietic
stem cells specify cellular product type and the target number
(or range) of cells requested. Processing orders for hematopoietic
stem cells specify manufacturing steps such as CD34 selection,
cryopreservation or thawing and desired cell dose. Release orders
specify the cell type and cell dose needed for administration.
When cryopreserved products are available for administration,
physicians can select individual products for release. Since tem-
plates are specific for individual treatment plans or protocols,
physician order choices are restricted by the requirements of
the protocol each patient has been registered to. This system
was implemented in June 2010 after extensive in-house planning,
development, validation and end-user training. This quality im-
provement process gave us the opportunity to review and im-
prove the workflow processes in all areas (clinical, collections,
registration, processing, information management) related to cel-
lular therapy.
